DEXCOM, INC. FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $4.7B |
| Gross margin | 60.1% |
| Operating income | $911.8M |
| Net income | $836.3M |
| Diluted EPS | $2.09 |
| Cash & equivalents | $917.7M |
| Total assets | $6.3B |
| Long-term debt | — not reported |
Key takeaway
Dexcom posted $4.66 billion in revenue and $836.3 million in net income for fiscal 2025, maintaining a 60.1% gross margin.
🔒 4 more takeaways in the full analysis
Beneath the surface
The company carries $1.24 billion in convertible notes (ConvertibleLongTermNotesPayable) against $917.7 million cash and a $1.5 billion total investment portfolio, meaning net debt is modest but not eliminated as headline cash figures alone might suggest.
🔒 3 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 7 more findings — plus insider trades, activist stakes, and 8-K events for DXCM.
Read the full analysis free Free account · 5 full analyses included · no card required